Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
ApexOnco Front Page
Recent articles
Ibtrozi breezes through FDA review and gives Nuvation its first approval.
LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.
Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.
Evopoint reveals intriguing but opaque first-in-human data for XNW27011.
As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.
The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.
But camizestrant’s use could depend on uptake of monitoring – for now.
